Dynamic Cell Therapies develops controllable CAR T cells that utilize a small molecule-antibody conjugate system to selectively target and activate immune responses against liquid and solid tumors. This technology addresses the challenge of minimizing off-tumor toxicity while enhancing the efficacy and safety of CAR T cell therapies in difficult-to-treat cancers.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CAR T-cell therapies face challenges in controlling their activity, leading to potential off-tumor toxicities and limiting their effectiveness against solid tumors. Precisely targeting and activating CAR T cells against tumors while minimizing harm to healthy tissues remains a significant hurdle.
Solution
Dynamic Cell Therapies is developing controllable CAR T-cell therapies that utilize a small molecule-antibody conjugate system to selectively target and activate immune responses against liquid and solid tumors. The platform uncouples tumor targeting from CAR T-cell activation, allowing physicians to dynamically control CAR T-cell activity by dosing the small molecule-antibody conjugate. This approach aims to improve the safety, efficacy, and durability of CAR T-cell therapies by minimizing off-target effects and maximizing on-target, on-tumor activity. The same small molecule can be coupled to different tumor-targeting antibodies, enabling redirection of the CAR T-cells if the tumor evades recognition.
Target Audience
The primary target audience includes hematologists, oncologists, and researchers focused on developing and administering advanced cancer immunotherapies, particularly CAR T-cell therapies.
Features
- CAR T-cells recognize an inert small molecule, preventing cross-reactivity with normal tissue.
- CAR T-cell activity is proportional to the dosage of the small molecule-antibody conjugate, allowing for titration of the immune response.
- Small molecule-antibody conjugates bind to specific tumor cell antigens, ensuring targeted delivery.
- Activated CAR T-cells release perforins to induce tumor cell death and cytokines to recruit and stimulate the body's natural immune cells.
- The platform allows for the use of multiple antibodies targeting various antigens coupled to the same small molecule to maximize efficacy and limit toxicity.